Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation

Pituitary

Volumn 15, Issue 3, 2012, Pages 342-349

  Syro, Luis V ^a   Sundsbak, Jamie L ^b   Scheithauer, Bernd W ^b   Toledo, Rodrigo A ^c   Camargo, Mauricio ^d   Heyer, Christina M ^b   Sekiya, Tomoko ^c   Uribe, Humberto ^e   Escobar, Jorge I ^f   Vasquez, Martin ^a   Rotondo, Fabio ^g   Toledo, Sergio P A ^c   Kovacs, Kalman ^g   Horvath, Eva ^g   Babovic Vuksanovic, Dusica ^b   Harris, Peter C ^b  

^a HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^e Clinica SOMA   (Colombia)

^f Clinica Las Americas   (Colombia)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Acromegaly; Adult polycystic kidney disease; Pituitary adenoma; Single nucleotide polymorphism; Somatostatin receptor 5

Indexed keywords

DNA; GROWTH HORMONE; OCTREOTIDE; POLYCYSTIN 1; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 5;

ACROMEGALY; ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CAVERNOUS SINUS; CHROMOSOME 16; CHROMOSOME ANALYSIS; COMPUTER MODEL; FAMILY HISTORY; FEMALE; GENE MUTATION; GROWTH HORMONE SECRETING ADENOMA; HEMIANOPIA; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; KIDNEY POLYCYSTIC DISEASE; LEUKOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SELLA TURCICA TUMOR; SEQUENCE ANALYSIS; ULTRASTRUCTURE;

ACROMEGALY; ADENOMA; ADULT; BASE SEQUENCE; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; PITUITARY GLAND; PITUITARY NEOPLASMS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMORPHISM, GENETIC; RECEPTORS, SOMATOSTATIN; TRPP CATION CHANNELS;

EID: 84867398358     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0325-0     Document Type: Article

References (39)

1. Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60:321-337
2. Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76(2):149-168
3. Melmed S (2006) Medical progress: acromegaly. N Eng J Med 355(24):2558-2573
4. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189-3202. doi:10.1172/JCI3937539375
5. Fajfr R, Muller B, Diem P (2002) Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease. Praxis 91(25-26):1123-1126
6. Kannabiran M, Singh V, Grewal S (2006) Acromegaly presenting as psychotic disorder in a family with familial autosomal dominant polycystic kidney disease. German J Psychiatry 9:136-138. http://www.gjpsy.uni-goettingen.de/gjp- article-kannabiran.pdf
7. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC (2007) Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18(7): 2143-2216. doi:10.1681/ASN.2006121387
8. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Torres VE, Harris PC (2009) Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75(8):848-855. doi:10.1038/ki.2008.686
9. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103(42):15558-15563. doi:10.1073/pnas.0603877103
10. Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP, Dahia PL (2007) Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 92(5):1934-1937. doi:10.1210/jc.2006-2394
11. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gundogdu S, De Menis E, Makinen MJ, Launonen V, Karhu A, Aaltonen LA (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777): 1228-1230. doi:10.1126/science.1126100
12. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68(1):206-216
13. Ben-Shlomo A, Melmed S (2010) Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 21(3):123-133. doi:10.1016/j.tem.2009.12.003
14. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20(3):157-198. doi:10.1006/frne.1999.0183
15. Reisine T, Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16(4):427-442
16. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99(4): 789-798
17. Filopanti M, Ronchi C, Ballare E, Bondioni S, Lania AG, Losa M, Gelmini S, Peri A, Orlando C, Beck-Peccoz P, Spada A (2005) Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 90(8): 4824-4828
18. Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79(3):724-729
19. Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M (2006) Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 59(3):274-279. doi:10.1136/jcp.2005.026914
20. Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A (2001) Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 73(5):344-351
21. Shimon I (2003) Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 20(3):265-269. doi:10.1385/ENDO:20:3:265
22. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156(1):65-74. doi:10.1530/eje.1.02313
23. van der Hoek J, Lamberts SW, Hofland LJ (2007) Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol 156(Suppl 1):S45-S51. doi:10.1530/eje.1. 02350
24. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5): 1509-1517
25. Bronstein MD (2006) Acromegaly molecular expression of somatostatin receptor subtypes and treatment outcome. Frontiers Horm Res 35:129-134
26. Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 12(4):297-303. doi:10.1007/s11102-009-0175-1
27. van der Lely AJ, de Herder WW, Lamberts SW (1999) New medical treatment for acromegaly. Pituitary 2(1):89-92
28. Vitale G, Pivonello R, Ferone D, De Martino MC, Auriemma RS, Caraglia M, Abbruzzese A, Lombardi G, Colao A (2004) The role of somatostatin receptors in the medical treatment of acromegaly. Dig Liver Dis 36(Suppl 1):S55-S59
29. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86(8):3809-3814
30. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P (2010) Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 5(5):783-789. doi:10.2215/CJN.05380709
31. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21(6):1052-1061. doi:10.1681/ASN.2009121291
32. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP (2009) Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 137(5): 1661-1668. doi:10.1053/j.gastro.2009.07.052 e1661-e1662
33. Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, O'Hare MJ, Ong AC (2007) Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney Int 72(2):157-165. doi:10.1038/sj.ki.5002229
34. Manara R, Maffei P, Citton V, Rizzati S, Bommarito G, Ermani M, Albano I, Della Puppa A, Carollo C, Pavesi G, Scanarini M, Ceccato F, Sicolo N, Mantero F, Scaroni C, Martini C (2011) Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature. J Clin Endocrinol Metab 96(5):1292-1300. doi:10.1210/jc.2010-2721
35. Sandford R, Sgotto B, Burn T, Brenner S (1996) The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome. Genomics 38(1):84-86. doi:10.1006/ geno.1996.0596
36. Johansson M, McKay JD, Wiklund F, Rinaldi S, Hallmans G, Balter K, Adami HO, Gronberg H, Stattin P, Kaaks R (2009) Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 18(5):1644-1650. doi:10.1158/1055-9965.EPI-08-0893
37. Nyegaard M, Borglum AD, Bruun TG, Collier DA, Russ C, Mors O, Ewald H, Kruse TA (2002) Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder. Mol Psychiatry 7(7):745-754. doi:10.1038/sj.mp.4001049
38. Li D, Tanaka M, Brunicardi FC, Fisher WE, Gibbs RA, Gingras MC (2011) Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival. Cancer. doi:10.1002/cncr.25858
39. Hassaneen W, Cahill DP, Fuller GN, Levine NB (2010) Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma. J Neurooncol 98(1):151-152. doi:10.1007/s11060-009-0048-5